Fast Five Quiz: Castration-Resistant Prostate Cancer

Kyle A. Richards, MD


December 02, 2020

Nearly all metastatic prostate cancers develop resistance to androgen deprivation therapy. When a patient with serum testosterone levels < 50 ng/dL has two to three consecutive rises in PSA levels at intervals of more than 2 weeks and/or documented disease progression based on the results of CT scan and/or bone scan, bone pain, or obstructive voiding symptoms, the disease is deemed castration resistant.

Learn more about nmCRPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.